Regenerative medicine company Mesoblast Ltd.’s stock sank nearly 57% on the news that it received a second U.S. FDA complete response letter (CRL) following the resubmission of its BLA for allogeneic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback